Abuse resistant drugs, method of use and method of making
View Patent ↗An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
1. An oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer, and a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an expansion layer comprising an expandable polymer, and wherein the barrier layer substantially covers the expansion layer.
3. The pharmaceutical composition of claim 1 , wherein the first polymer and second polymer, independent from each other, are selected from the group consisting of acrylic polymers and acrylic copolymers.
4. The pharmaceutical composition of claim 3 , wherein the acrylic polymers and acrylic copolymers are selected from the group consisting of: quarternary ammonium acrylic polymers, methacrylic polymers, ethyl acrylic polymers, methyl methyacrylic polymers, and copolymers thereof.
5. The pharmaceutical composition of claim 1 , wherein the first polymer and second polymer comprise different polymers.
6. The pharmaceutical composition of claim 1 , wherein the first polymer and second polymer comprise the same polymer.
7. The pharmaceutical composition of claim 1 , wherein the first polymer comprises a copolymer of ethyl acrylate and methyl methacrylate.
8. The pharmaceutical composition of claim 1 , wherein the second polymer comprises a copolymer of ethyl acrylate and methyl methacrylate.
9. The pharmaceutical composition of claim 1 , wherein the diffusion layer comprises a pore forming agent.
10. The pharmaceutical composition of claim 1 , prepared by a process comprising the steps of: forming the barrier layer, and applying the diffusion layer over the barrier layer immediately after forming the barrier layer.
11. The pharmaceutical composition of claim 10 , wherein the process further comprises curing the barrier layer and the diffusion layer together after applying the diffusion layer over the barrier layer.
12. The pharmaceutical composition of claim 1 , prepared by a process comprising the steps of: forming the barrier layer, curing the barrier layer, and applying the diffusion layer over the barrier layer.
13. The pharmaceutical composition of claim 12 , wherein the process further comprises curing the diffusion layer after applying the diffusion layer over the barrier layer.
14. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is physically compromised and particles of the pharmaceutical composition containing the expansion layer are formed and exposed to a liquid, the expandable polymer of the expansion layer absorbs at least a portion of the liquid.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is administered in an intact form, the first polymer of the barrier layer is substantially undissolved in the GI tract.
16. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is physically compromised and particles of the pharmaceutical composition containing the diffusion layer and the barrier layer are formed, the bond between the diffusion layer and barrier layer within the particles is substantially preserved.
17. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is configured such that when the pharmaceutical composition is administered in physically compromised form to a subject, the Cmax and/or AUC achieved after a time period selected from the group consisting of 2 hours, 4, hours, 8 hours, 12 hours, 24 hours, and 48 hours after administration is substantially the same or lower than the Cmax and/or AUC achieved when the pharmaceutical composition is administered in an intact form.
18. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises an additional release layer, wherein the additional release layer is an immediate release layer substantially covering the diffusion layer, wherein the additional release layer comprises at least one additional drug.
19. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in a pharmaceutical dosage form selected from the group consisting of a tablet, a capsule, a micro tablet, granules, pellets, a lozenge, a lollipop, and a coated capsule.
20. The pharmaceutical composition of claim 1 , wherein the drug is selected from the group consisting of central nervous system stimulants and central nervous system depressants.